Real-World Treatment Patterns Among Pediatric and Adult Patients with Crohn’s Disease in the United States
Open Access
- 8 April 2025
- journal article
- research article
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 12 (2) , 201-211
Abstract
Background The advent of biologics has expanded treatment options for Crohn’s disease (CD). This study assessed treatment patterns in pediatric and adult patients with CD in the United States during 1- and 3-year follow-up periods. Methods This retrospective, claims-based cohort study utilized the Merative™ MarketScan® Research Databases from January 1, 2014, to December 31, 2021. The index date was the date of the first CD diagnosis during the identification period. Among pediatric and adult CD cohorts, patients were stratified into two subgroups: (a) previously diagnosed (presence of a CD claim) and (b) newly diagnosed (absence of a CD claim) in the 12-month pre-index period. Results were summarized descriptively. Results Data from 2809 pediatric and 25,940 adult patients were analyzed at 1-year follow-up. Mean age in years was 13.5 for pediatric and 46.0 for adult patients. Combination therapies were more common in pediatric versus adult patients, especially among those newly diagnosed with CD (38.2% vs 13.9%). A higher percentage of pediatric patients were prescribed biologics than adults (35.1% vs 24.3%). Numerically shorter time from diagnosis to corticosteroid initiation was observed in pediatric versus adult patients (9.5 vs 35 days). Higher persistence to biologics was observed in pediatric versus adult patients (94.6% vs 87.1%). Conclusions Combination therapies with biologics were more frequent among pediatric patients than adults. Although the overall treatment pattern among pediatric and adult patients was similar, early initiation of corticosteroids and adoption of biologics were more frequently observed in pediatric than adult patients, consistent with pediatric CD presenting with more aggressive disease.Keywords
Funding Information
- Eli Lilly and Company
This publication has 33 references indexed in Scilit:
- Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseJournal of Crohn's and Colitis, 2014
- Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's DiseaseGastroenterology, 2014
- Management of Active Crohn DiseaseJAMA, 2013
- Mucosal Healing in Crohnʼs DiseaseInflammatory Bowel Diseases, 2013
- Pediatric clinical trialsPerspectives in Clinical Research, 2013
- Impact of Disease and Treatments on Growth and Puberty of Pediatric Patients with Inflammatory Bowel DiseaseDigestion, 2012
- Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2010
- Dose-related patterns of glucocorticoid-induced side effectsAnnals of the Rheumatic Diseases, 2009
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United StatesClinical Gastroenterology and Hepatology, 2007